Viral vectors for dendritic cell-based immunotherapy.
Transduction of dendritic cells (DCs) by viral vectors genetically engineered to express tumor-associated antigens (TAAs) or cytokines can produce a high level of transgene expression and is an attractive approach for DC-based immunotherapy. Ex vivo transduction allows the control of DC quality, antigen quantity and site of DC reinjection. This review evaluates the viral vectors currently being developed for use in DC-based immunotherapy.
Jenne
L
L
Department Dermatology, University of Erlangen-Nürnberg, Hartmannstrasse 14, D-91052, Erlangen, Germany.
Schuler
G
G
Steinkasserer
A
A
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003713:Dendritic Cells / Q000637:transplantation*; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000276:immunology / Q000627:therapeutic use; D006801:Humans; D014765:Viral Vaccines / Q000235:genetics* / Q000276:immunology* / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D014765:Viral Vaccines